Novartis is the latest drugmaker to invest in its Chinese footprint, with a pledge of more than 3.3 billion yuan ($480 million) to bolster two
WuXi AppTec’s sales are becoming even more increasingly dependent on the US despite the service provider not yet fully shaking off concerns over its ties
Parkinson’s stem cell therapy developer Oryon Cell Therapies started out Monday morning with three announcements: It enlisted Ron Cohen as its new CEO, netted an
Biotech takeover specialist Kevin Tang is consolidating control at Aurinia Pharmaceuticals, and has replaced the CEO and C-suite at the company, according to a securities
Plus, news about Opdivo: 📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line
In a rare move, the FDA last week posted photographs of dilapidated buildings as part of a warning letter for a Daman, India-based drug manufacturing facility.
The photographs are the latest sign that FDA Commissioner …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844